GlassScriptPhysician profile
Robert S Seibt
NPI 1275578890
$3,140.84
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,849 · 2020: $750 · 2021: $531 · 2022: $11.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.66 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $365.03 | 2019 | |
| Pfizer INC. | $324.62 | 2019-2021 | |
| Janssen Biotech, INC. | $296.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $215.73 | 2019-2021 | |
| Leo Pharma INC. | $187.86 | 2019-2021 | |
| Lilly USA, LLC | $120.12 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $111.62 | 2019 | |
| Prugen, INC. Pharmaceuticals | $108.48 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.03 | 2020-2021 | |
| Galderma Laboratories, L.P. | $83.28 | 2019-2020 | |
| Genzyme Corporation | $82.23 | 2019-2021 | |
| Encore Dermatology INC. | $82.11 | 2019-2020 | |
| Sandoz INC. | $75.79 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $69.21 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.51 | 2020-2021 | |
| Epi Health, LLC | $49.70 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $45.17 | 2020-2021 | |
| Journey Medical Corporation | $44.95 | 2019-2020 | |
| Dermira, INC. | $36.94 | 2020 | |
| Mission Pharmacal Company | $33.52 | 2019-2021 | |
| Almirall LLC | $29.34 | 2020-2021 | |
| Celgene Corporation | $27.30 | 2019 | |
| Biofrontera INC. | $23.56 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.35 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.12 | 2021 | |
| Aclaris Therapeutics, INC. | $15.72 | 2019 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Amgen INC. | $14.69 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Seibt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.